Download PDF
Thromb Haemost 1991; 66(01): 178-188
DOI: 10.1055/s-0038-1646387
Review Article
Schattauer GmbH Stuttgart

Platelet Transfusions a Constantly Evolving Therapy

Sherrill J Slichter
Further Information

Publication History

Publication Date:
25 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 NIH Consensus Development Conference Statement. 1986 6. (Suppl. 7)
    PubMedGoogle Scholar
  • 2 Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962; 266: 905
    CrossrefPubMedGoogle Scholar
  • 3 Slichter SJ, Harker LA. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 1978; 7: 52
    PubMedGoogle Scholar
  • 4 Roy AJ, Jaffe N, Djerassi I. Prophylactic platelet transfusions in children with acute leukemia: a dose response study. Transfus 1973; 13: 283
    PubMedGoogle Scholar
  • 5 Aderka D, Praff G, Santo M, Weinberger A. Bleeding due to thrombocytopenia in acute leukemias and reevaluation of the prophylactic platelet transfusion policy. Am J Med Sci 1986; 291: 147
    CrossrefPubMedGoogle Scholar
  • 6 Solomon J, Bokefkamp T, Fahey JL. et al. Platelet prophylaxis in acute non-lymphocytic leukemia. Lancet 1978; 1: 267
    PubMedGoogle Scholar
  • 7 Murphy S, Litwin S, Koch P. et al. The indications for platelet transfusion in children with acute leukemia. Am J Hem 1982; 12: 347
    CrossrefPubMedGoogle Scholar
  • 8 Harker LA, Slichter SJ. The bleeding time as a screening test for evaluating platelet function. N Engl J Med 1972; 287: 155
    CrossrefPubMedGoogle Scholar
  • 9 Welsh J, Burgos H, Batchelor JR. The immune response to allogeneic rat platelets; Ag-B antigens in matrix form lacking la. Immunology 1977; 7: 267
    PubMedGoogle Scholar
  • 10 Batchelor JR, Welsh KI, Burgos H. Transplantation antigens per se are poor immunogens within a species. Nature 1978; 273: 54
    CrossrefPubMedGoogle Scholar
  • 11 Eernisse JG, Brand A. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Exp Hematol 1981; 9: 77
    PubMedGoogle Scholar
  • 12 Schiffer CA, Dutcher JP, Aisner J. et al. A randomized trial of leukocyte-depleted platelet transfusions to modify alloimmunization in patients with leukemia. Blood 1983; 62: 815
    PubMedGoogle Scholar
  • 13 Murphy MF, Metcalfe P, Thomas H. et al. Use of leukocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 1986; 62: 529
    CrossrefPubMedGoogle Scholar
  • 14 Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988; 71: 1402
    PubMedGoogle Scholar
  • 15 Andreu G, Dewailly J, Leberre C. et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988; 72: 964
    PubMedGoogle Scholar
  • 16 Saarinen UM, Kekomaki R, Siimes MA, Myllyla G. Effective prophylaxis against platelet refractoriness in multi-transfused patients by use of leukocyte-free blood components. Blood 1990; 75: 512
    PubMedGoogle Scholar
  • 17 van Marwijk Kooy M, van Prooijen HC, Moes M. et al. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial. Blood 1991; 77: 201
    PubMedGoogle Scholar
  • 18 Nussenzweig MC, Steinman RM. Contribution of dendritic cells to stimulation of the murine syngeneic mixed leukocyte reaction. J Exp Med 1980; 151: 1196
    CrossrefPubMedGoogle Scholar
  • 19 Tew JG, Thorbecke GH, Steinman RM. Dendritic cells in the immune-response: Characteristics and recommended nomenclature. J Reticuloendothel Soc 1982; 31: 371
    PubMedGoogle Scholar
  • 20 Kripke ML. Immunologic unresponsiveness induced by ultraviolet radiation. Immunol Rev 1984; 80: 87
    CrossrefPubMedGoogle Scholar
  • 21 Spellman CW, Daynes RA. Modification of immunologic potential by ultraviolet radiation. II. Generation of suppressor cells in short-term UV-irradiated mice. Transplantation 1977; 24: 120
    PubMedGoogle Scholar
  • 22 Deeg HJ, Sigaroudinia M. Ultraviolet B-induced loss of HLA Class II antigen expression on lymphocytes is dose, time, and locus dependent. Exp Hematol 1990; 18: 2726
    PubMedGoogle Scholar
  • 23 Krutmann J, Khan IU, Wallis RS. et al. Cell membrane is a major locus for ultraviolet B-induced alterations in accessory cells. J Clin Invest 1990; 85: 1529
    CrossrefPubMedGoogle Scholar
  • 24 Slichter SJ, Deeg HJ, Kennedy MS. Prevention of platelet alloimmunization in dogs with systemic cyclosporine and by UV-irradiation or cyclosporineloading of donor platelets. Blood 1987; 69: 414
    PubMedGoogle Scholar
  • 25 Pamphilon DH, Potter M, Cutts M. et al. Platelet concentrates irradiated with ultraviolet light retain satisfactory in vitro storage characteristics and in vivo survival. Br J Haematol 1990; 75: 240
    CrossrefPubMedGoogle Scholar
  • 26 Andreu G, Boccaccio C, Lecrubier C. et al. Ultraviolet irradiation of platelet concentrates: Feasibility in transfusion practice. Transfusion 1990; 30: 401
    CrossrefPubMedGoogle Scholar
  • 27 Buchholz DH, Miripol J, Aster RH. et al. Ultraviolet irradiation of platelets to prevent recipient alloimmunization. (Abstract) Transfusion 1988; 28: 26S
    PubMedGoogle Scholar
  • 28 Capon SM, Sacher RA, Deeg HJ. Effective ultraviolet irradiation of platelet concentrates in teflon bags.. Transfusion, in press
    PubMedGoogle Scholar
  • 29 Slichter SJ. Prevention of platelet alloimmunization. In Murawski K. (ed.) Transfusion Medicine: Recent Technological Advances. pg. 83 American Association of Blood Banks: Arlington, VA.: 1985
    Google Scholar
  • 30 Tejada F, Bias WB, Santos GW, Zieve PD. Immunologic response of patients with acute leukemia to platelet transfusions. Blood 1973; 42: 405
    PubMedGoogle Scholar
  • 31 Howard JE, Perkins HA. The natural history of alloimmunization to platelets. Transfusion 1978; 18: 496
    CrossrefPubMedGoogle Scholar
  • 32 Holohan TV, Terasaki PI, Diesseroth AB. Suppression of transfusion-related alloimmunization in intensively treated cancer patients. Blood 1981; 58: 122
    PubMedGoogle Scholar
  • 33 Lee EJ, Schiffer CA. Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients. Blood 1987; 70: 1727
    PubMedGoogle Scholar
  • 34 Murphy MF, Metcalfe P, Ord J. et al. Disappearance of HLA and platelet-specific antibodies in acute leukaemia patients alloimmunized by multiple transfusions. Br J Haematol 1987; 67: 255
    CrossrefPubMedGoogle Scholar
  • 35 McGrath K, Wolf M, Bishop J. et al. Transient platelet and HLA antibody formation in multitransfused patients with malignancy. Br J Haematol 1988; 68: 345
    CrossrefPubMedGoogle Scholar
  • 36 Pamphilon DH, Farrell DH, Donaldson C. et al. Development of lymphocytotoxic and platelet reactive antibodies: A prospective study in patients with acute leukemia. Vox Sang 1989; 57: 177
    CrossrefPubMedGoogle Scholar
  • 37 Ford JM, Brown LM, Cullen MH. et al. Combined granulocyte and platelet transfusions. Development of alloimmunization as reflected by decreasing cell recovery values. Transfusion 1982; 22: 498
    PubMedGoogle Scholar
  • 38 Dutcher JP, Schiffer CA, Aisner J, Wiernik PH. Long-term followup of patients with leukemia receiving platelet transfusions: Identification of a large group of patients who do not become alloimmunized. Blood 1981; 58: 1007
    PubMedGoogle Scholar
  • 39 Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 1965; 26: 732
    PubMedGoogle Scholar
  • 40 Lee EJ, Schiffer CA. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion 1989; 29: 384
    PubMedGoogle Scholar
  • 41 Duquesnoy RJ, Anderson AJ, Tomasulo PA, Aster RH. ABO compatibility and platelet transfusions of alloimmunized thrombocytopenic patients. Blood 1979; 54: 595
    PubMedGoogle Scholar
  • 42 Heal JM, Blumberg N, Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987; 70: 23
    PubMedGoogle Scholar
  • 43 Brand A, Sintnicolaas K, Claas FHJ, Eernisse JG. ABH antibodies causing platelet transfusion refractoriness. Transfusion 1986; 26: 463
    CrossrefPubMedGoogle Scholar
  • 44 Freireich EJ, Kliman A, Gaydos LA. et al. Response to repeated platelet transfusion from the same donor. Ann Intern Med 1963; 59: 277
    CrossrefPubMedGoogle Scholar
  • 45 McFarland JG, Anderson AJ, Slichter SJ. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates. Br J Haematol 1989; 73: 380
    CrossrefPubMedGoogle Scholar
  • 46 Tosato G, Appelbaum FR, Deisseroth AB. HLA-matched platelet transfusion therapy of severe aplastic anemia. Blood 1978; 52: 846
    PubMedGoogle Scholar
  • 47 Shulman NR. Immunological considerations attending platelet transfusion. Transfusion 1966; 6: 39
    CrossrefPubMedGoogle Scholar
  • 48 Svejgaard A, Kissmeyer-Nielsen F, Thorsby E. HL-A typing of platelets. In Terasaki PI. (ed.) Histocompatibility Testing. 1970. pg. 160 Munksgaard: Copenhagen, Denmark.: 1970
    Google Scholar
  • 49 Duquesnoy RJ, Filip DJ, Tomasulo PA. et al. Role of HLA-C matching in histocompatible platelet transfusion therapy of alloimmunized thrombocytopenic patients. Transplant Proc 1977; 9: 1829
    PubMedGoogle Scholar
  • 50 van Rood JJ, van Leeuwen A, Keuning JJ. et al. The serological recognition of the human MLC determinants using a modified cytotoxicity technique. Tissue Antigens 1975; 5: 73
    PubMedGoogle Scholar
  • 51 Yankee RA, Grumet FC, Rogentine GN. Platelet transfusion therapy. The selection of compatible donors for refractory patients by lymphocyte HLA typing. N Engl J Med 1969; 281: 1208
    PubMedGoogle Scholar
  • 52 Yankee RA, Graff KS, Dowling R. et al. Selection of unrelated compatible platelet donors by lymphocyte HL-A matching. N Engl J Med 1973; 288: 760
    CrossrefPubMedGoogle Scholar
  • 53 Duquesnoy RJ, Filip DJ, Rodey GE. et al. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977; 2: 219
    CrossrefPubMedGoogle Scholar
  • 54 Oldfather JW, Mora A, Phelan D. et al. The occurrence of crossreactive "public" antibodies in the sera of highly sensitized dialysis patients. Transplant Proc 1983; 15: 1212
    PubMedGoogle Scholar
  • 55 Schwartz BD, Luehrman LK, Rodey GE. Public antigenic determinant on a family of HLA-B molecules. Basis for crossreactivity and a possible link with disease predisposition. J Clin Invest 1979; 64: 938
    PubMedGoogle Scholar
  • 56 Slichter SJ, Teramura G. Frequency of platelet-specific alloantibodies in platelet refractory thrombocytopenic patients. (Abstract). Blood 1988; 72 (Suppl. 1) 286a
    PubMedGoogle Scholar
  • 57 Kickler T, Kennedy SD, Braine HG. Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion 1990; 30: 622
    CrossrefPubMedGoogle Scholar
  • 58 Schiffer CA. Management of patients refractory to platelet transfusion — An evaluation of methods of donor selection. Prog Hematol 1987; 15: 91
    PubMedGoogle Scholar
  • 59 Saji H, Maruya E, Fujii H. et al. New platelet antigen, Siba involved in platelet transfusion refractoriness in a Japanese man. Vox Sang 1989; 56: 283
    PubMedGoogle Scholar
  • 60 Iikeda H, Mitani T, Ohnuma M. et al. A new platelet-specific antigen, Naka involved in the refractoriness of HLA-matched platelet transfusion. Vox Sang 1989; 57: 213
    CrossrefPubMedGoogle Scholar
  • 61 Kiss JE, Salamon DJ, Wilson J. et al. Suitability of liquid-stored donor platelets in platelet compatibility testing. Transfusion 1989; 29: 405
    CrossrefPubMedGoogle Scholar
  • 62 Pollack MS, Zaroulis CG, Klainbard JMI. et al. Retention of HLA antigens on previously frozen human platelets. Transfusion 1980; 20: 458
    CrossrefPubMedGoogle Scholar
  • 63 Helmerhorst FM, ten Berge ML, van der Plas-van Dalen CM. et al. Platelet freezing for serological purposes with and without a cryopreservative. Vox Sang 1984; 46: 318
    CrossrefPubMedGoogle Scholar
  • 64 Lizak GE, Grumet FC. Storage of reagent platelets for anti-platelet antibody testing in the 51Cr platelet lysis assay. J Clin Pathol 1979; 32: 191
    CrossrefPubMedGoogle Scholar
  • 65 Kickler TS, Nedd PM, Braine HG. Platelet Crossmatching. A direct approach to the selection of platelet transfusions for the alloimmunized thrombocytopenic patient. AJCP 1988; 90: 69
    PubMedGoogle Scholar
  • 66 Rachel JM, Summers TC, Sinor LT, Plapp FV. Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing. AJCP 1988; 90: 63
    PubMedGoogle Scholar
  • 67 Freedman J, Hooi C, Garvey MB. Prospective platelet crossmatching for selection of compatible random donors. Br J Haematol 1984; 56: 9
    CrossrefPubMedGoogle Scholar
  • 68 Freedman J, Garvey MB, Salomon de Friedberg Z. et al. Random donor platelet crossmatching: Comparison of four platelet antibody detection methods. Am J Hematol 1988; 28: 1
    CrossrefPubMedGoogle Scholar
  • 69 O'Connell BA, Schiffer CA. Donor selection for alloimmunized patients by platelet crossmatching of random-donor platelet concentrates. Transfusion 1990; 30: 314
    CrossrefPubMedGoogle Scholar
  • 70 Freedman J, Gafni A, Garvey MB, Blanchette V. A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients. Transfusion 1989; 29: 201
    CrossrefPubMedGoogle Scholar
  • 71 Kekomaki R, Elfenbein G, Gardner R. et al. Improved response of patients refractory to random-donor platelet transfusions by intravenous gamma globulin. Am J Med 1984; 76: 199
    PubMedGoogle Scholar
  • 72 Bierling P, Cordonnier C, Rodet M. et al. High dose intravenous gammaglobulin and platelet transfusions in leukaemic HLA-immunized patients. Scand J Haematol 1984; 33: 215
    PubMedGoogle Scholar
  • 73 Junghans RP, Ahn YS. High-dose intravenous gamma globulin to suppress alloimmune destruction of donor platelets. Am J Med 1984; 76: 204
    CrossrefPubMedGoogle Scholar
  • 74 Kickler T, Braine HG, Piantadosi S. et al. A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 1990; 75: 313
    PubMedGoogle Scholar
  • 75 Ziegler ZR, Shadduck RK, Rosenfeld CS. et al. High-dose intravenous gamma globulin improves responses to single-donor platelets in patients refractory to platelet transfusion. Blood 1987; 70: 1433
    PubMedGoogle Scholar
  • 76 Atrah HI, Sheehan T, Gribben J. et al. Improvement of post platelet transfusion increments following intravenous immunoglobulin therapy for leukaemic HLA-immunized patients. Scand J Haematol 1986; 36: 160
    PubMedGoogle Scholar
  • 77 Becton DL, Kinney TR, Schaffee S. et al. High-dose intravenous immunoglobulin for severe platelet alloimmunization. Pediatrics 1984; 74: 1120
    PubMedGoogle Scholar
  • 78 Knupp C, Chamberlain JK, Raab SO. High-dose intravenous gamma globulin in alloimmunized platelet transfusion recipients. Blood 1985; 65: 776
    PubMedGoogle Scholar
  • 79 Lee EJ, Norris D, Schiffer CA. Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion. Transfusion 1987; 27: 245
    CrossrefPubMedGoogle Scholar
  • 80 Schiffer CA, Hogge DE, Aisner J. et al. High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood 1984; 64: 937
    PubMedGoogle Scholar
  • 81 Slichter SJ, Deeg HJ, Storb R. Prevention and reversal of platelet alloimmunization with cyclosporine A. (Abstract). Blood 1981; 51 (Suppl. 1) 186a
    PubMedGoogle Scholar
  • 82 Yamamoto M, Ideguchi H, Nishimura J. et al. Treatment of platelet-alloimmunization with cyclosporin A in a patient with aplastic anemia. Am J Hematol 1990; 33: 220
    CrossrefPubMedGoogle Scholar
  • 83 Tilly H, Azagury M, Bastit D. et al. Cyclosporin for treatment of life-threatening alloimmunization. Am J Hematol 1990; 34: 75
    CrossrefPubMedGoogle Scholar
  • 84 Bartholomew JR, Salgia R, Bell WR. Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med 1989; 149: 1959
    CrossrefPubMedGoogle Scholar
  • 85 Gardner FH, Helmer RE. Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA 1980; 243: 35
    PubMedGoogle Scholar
  • 86 Garewal HS, Durie BGM. Anti-fibrinolytic therapy as aminocaproic acid for the control of bleeding in thrombocytopenic patients. Scand J Haematol 1985; 35: 497
    PubMedGoogle Scholar
  • 87 Gallardo RL, Gardner FH. Antifibrinolytic therapy for bleeding control during remission induction for acute leukemia. (Abstract). Blood 1983; 62 (Suppl. 1) 202a
    PubMedGoogle Scholar
  • 88 Ben-Bassat I, Douer D, Ramot B. Tranexamic acid therapy in acute myeloid leukemia: Possible reduction of platelet transfusions. Eur J Haematol 1990; 45: 86
    PubMedGoogle Scholar
  • 89 Bishop JF, McGrath K, Wolf MM. et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988; 71: 383
    PubMedGoogle Scholar
  • 90 Rock G, Sherring VA, Tittley P. Five-day storage of platelet concentrates. Transfusion 1984; 24: 147
    CrossrefPubMedGoogle Scholar
  • 91 Murphy S, Holme S, Nelson E, Carmen R. Paired comparison of the in vivo and in vitro results of storage of platelet concentrates in two containers. Transfusion 1984; 24: 31
    CrossrefPubMedGoogle Scholar
  • 92 Simon TL, Nelson EJ, Murphy S. Extension of platelet concentrate storage to 7 days in second-generation bags. Transfusion 1987; 27: 6
    CrossrefPubMedGoogle Scholar
  • 93 Holme S, Heaton A, Momoda G. Evaluation of a new, more oxygen-permeable, polyvinylchloride container. Transfusion 1989; 29: 159
    CrossrefPubMedGoogle Scholar
  • 94 Snyder EL, Ezekowitz M, Aster R. et al. Extended storage of platelets in a new plastic container. II. in vivo response to infusion of platelets stored for 5 days. Transfusion 1985; 25: 209
    CrossrefPubMedGoogle Scholar
  • 95 Rock G, Tittley P, McCombie N. 5-day storage of single-donor platelets obtained using a blood cell separator. Transfusion 1989; 29: 288
    CrossrefPubMedGoogle Scholar
  • 96 Shanwell A, Gulliksson H, Berg BK. et al. Evaluation of platelets prepared by apheresis and stored for 5 days. in vitro and in vivo studies. Transfusion 1989; 29: 783
    CrossrefPubMedGoogle Scholar
  • 97 Slichter SJ, Harker LA. Preparation and storage of platelet concentrates. I. Factors influencing the harvest of viable platelets from whole blood. Br J Haematol 1976; 34: 395
    PubMedGoogle Scholar
  • 98 Hogge DE, Thompson BW, Schiffer CA. Platelet storage for 7 days in second-generation blood bags. Transfusion 1986; 26: 131
    CrossrefPubMedGoogle Scholar
  • 99 Schiffer CA, Lee EJ, Ness PM, Reilly J. Clinical evaluation of platelet concentrates stored for one to five days. Blood 1986; 67: 1591
    PubMedGoogle Scholar
  • 100 Lazarus HM, Herzig RH, Warm SE, Fishman DJ. Transfusion experience with platelet concentrates stored for 24 to 72 hours at 22°C. Transfusion 1982; 22: 39
    CrossrefPubMedGoogle Scholar
  • 101 Peter-Salonen K, Bucher U, Nydegger UE. Comparison of posttransfusion recoveries achieved with either fresh or stored platelet concentrates. Blut 1987; 54: 207
    CrossrefPubMedGoogle Scholar
  • 102 Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: Evidence for a fixed platelet requirement. Blood 1985; 66: 1105
    PubMedGoogle Scholar
  • 103 Bareford D, Chandler ST, Hawker RJ. et al. Splenic platelet-sequestration following routine blood transfusion is reduced by filtered/washed blood products. Br J Haematol 1987; 67: 177
    CrossrefPubMedGoogle Scholar
  • 104 Lim S, Boughton BJ, Bareford D. Thrombocytopenia following routine blood transfusion: Microaggregate blood filters prevent worsening thrombocytopenia in patients with low platelet counts. Vox Sang 1989; 56: 40
    CrossrefPubMedGoogle Scholar